A missed opportunity
02/05/24 -"CureVac did not really tidy things up. The cost-cutting measures, as presented, are insufficient and do not meet our ideal scenario of a focused and well-prioritised R&D pipeline. Investors may ..."
Pages
51
Language
English
Published on
02/05/24
You may also be interested by these reports :
17/05/24
We have incorporated higher royalty payments in 2024 related to the sale of the generic version of sodium oxybate (medicine to treat symptoms of ...
15/05/24
The Q1 results surpassed the consensus estimates, driven by a sustained strong performance from the strategic products. The management nonetheless ...
15/05/24
Merck started the year well, with Electronics being the largest contributor, demonstrating organic sales growth after several stagnant quarters. ...
15/05/24
The Q1 results largely met the consensus, as the firm’s key blood-plasma-derived proteins witnessed strong demand, profitability continued to expand ...